The UK Biobank’s extensive phenotypic and multi-omics dataset, linked to electronic health records, offers an unparalleled opportunity to conduct precision medicine research in inflammatory diseases (e.g., asthma, psoriasis, atopic dermatitis, rheumatoid arthritis, immunoglobulin G4-related disease). This project will leverage these integrated data to generate well-defined patient cohorts, deepen understanding of disease mechanisms, and support development of precision-targeted therapies.
Objectives:
(a) Characterize the epidemiology, severity, and subtypes of inflammatory diseases.
(b) Identify areas of unmet medical need to inform precision therapeutic strategies and drug development.
(c) Quantify disease burden-including patient-reported outcomes-and evaluate progression using clinical events and disease activity scores.
(d) Describe the current treatment landscape, including usage patterns, long-term outcomes, and real-world comparative effectiveness and safety.
(e) Conduct comprehensive multi-omics analyses to identify and validate novel targets, advancing personalized and efficient treatment approaches.
(f) Develop and/or validate predictive models to identify high-risk individuals and those most likely to benefit from specific therapies, integrating phenotypic, clinical, and molecular data.
Scientific rationale:
Inflammatory diseases are clinically and biologically heterogeneous, presenting major challenges for treatment. Drug development is hampered by variable immune pathways, frequent comorbidities, and limited predictive biomarkers. The UK Biobank’s standardized and generalizable data enable high-resolution analysis of disease trajectories, patient stratification, and therapeutic response-paving the way for more effective, individualized care through precision medicine.
